Track topics on Twitter Track topics that are important to you
Pirfenidone inhibits post-traumatic proliferative vitreoretinopathy Eye advance online publication, March 17 2017. doi:10.1038/eye.2017.21 Authors: B N M K Khanum, R Guha, V P Sur, S Nandi,...
FDA concurs with add-on placebo controlled phase 2/3 clinical trial for PBI-4050 in combination with nintedanib Prometic to also conduct placebo controlled phase 2/3 PBI-4050 Monotherapy cl...
About Idiopathic Pulmonary FibrosisIdiopathic pulmonary fibrosis belongs to a group of lung diseases known as interstitial lung diseases. It affects people in the age group 5070 years. Diagnosis is ef...
PurposeThe purpose of the study was to evaluate the efficacy and safety of intravitreal pirfenidone for inhibition of proliferative vitreoretinopathy (PVR) in a model of penetrating ocular injury.Pati...
Idiopathic pulmonary fibrosis (IPF) is characterized by excessive deposition of extracellular matrix, in particular collagens. Two IPF therapeutics, nintedanib and pirfenidone, decelerate lung functio...
Idiopathic pulmonary fibrosis (IPF) is a progressive, fibrotic, fatal lung disease associated with inevitable loss of lung function. The prognosis is poor, with a median survival of 2.5-3.5 years afte...
In glaucoma surgery, fibrotic processes occur, leading to impairment of liquid outflow. Activated fibroblasts are responsible for postoperative scarring. The transforming growth factor-β (TGF-β) pat...
Gastroesophageal reflux disease is a potential risk factor for idiopathic pulmonary fibrosis (IPF) progression; however, the impact of antacid therapy (AAT) is under debate.